Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine